



Results Report **2025**



Isingoma Christopher
delivers biological
samples from a local
clinic to the Kayunga
Regional Referral
Hospital in Kayunga,
Uganda



The Global Fund/Fredrik Lemeryd

Meeting the moment

The Global Fund partnership is **meeting the global health funding crisis with steadfast commitment to our mission** – focusing on the people and communities we serve and staying true to our values.


Leveraging our key strengths of **agility, partnership, organizational maturity and resilience**, we are responding to these external shocks and working hard to limit operational disruption.

We recognize **that we need to continue to evolve and adapt to the rapidly changing context. We are committed to making bold and transformative changes.**

We are recalibrating our grants, enhancing precision, and strengthening strategic frameworks for greater results.

2025 Results Reports

Key results for 2024



25.6
million

people on **antiretroviral therapy for HIV** in 2024.



7.4
million

people **treated for tuberculosis** in 2024.



162
million


insecticide-treated mosquito nets distributed to fight malaria in 2024.

HIV Progress toward global targets




AIDS-related deaths: progress toward the UNAIDS target

In countries where the Global Fund invests



New HIV infections: progress toward the UNAIDS target

In countries where the Global Fund invests



“Continuation of recent trend” projection is based on the continuation of 2019-2024 trends. “Global target pathway to 2030” is based on the target from UNAIDS 2025 targets to end AIDS, 2021 update. Countries that have recently received Global Fund HIV and AIDS funding and have reported programmatic results over the past two cycles.



HIV Trends



Trends in AIDS-related deaths

In countries where the Global Fund invests



● With prevention and ARVs (actual) ○ If there had been no prevention or ARVs % change, 2002-2024



Trends in new HIV infections

In countries where the Global Fund invests

● With prevention and ARVs (actual) ○ If there had been no prevention or ARVs % change, 2002-2024



HIV burden estimates from UNAIDS, 2025 release. Estimation of “no prevention or ARVs” trends from Goals Model and AIDS Impact Model (AIM).




HIV Key results for 2024 in countries where we invest




25.6 million

People on antiretroviral therapy for HIV*


People living with HIV who know their status



People living with HIV receiving ARVs



People living with HIV with suppressed viral load



*Programmatic results achieved during 2024 by countries and regions where the Global Fund invests. Progress graphs are based on latest published data from WHO (2024 release for TB and malaria) and UNAIDS (2025 release). Malaria mosquito net coverage calculated based on 38 African countries for which data is available from WHO/Malaria Atlas Project estimates.



Key Results

In countries where the Global Fund invests:

25.6M

People were on **antiretroviral therapy for HIV** in 2024, up from 17.5 million in 2017. Coverage increased from 22% in 2010 to 79% in 2024. Global target: 90% by 2025.

12.3M

People were **reached with HIV prevention services** in 2024, including 7.7 million people from key populations and 3 million young people.

1.4M

People received **antiretroviral pre-exposure prophylaxis (PrEP)** in 2024.

74%

Of people **living with HIV had a suppressed viral load** in 2024, up from 15% in 2015. Global target: 86% by 2025.

46.6M

HIV tests were taken (including 11.7 million by priority and key populations). People living with HIV with knowledge of their status increased from 61% in 2015 to 88% in 2024. Global target: 95% by 2025.

648K

Mothers living with HIV received medicine to keep them alive and prevent transmitting HIV to their babies in 2024. Coverage increased from 49% in 2010 to 85% in 2024. Global target: 100% by 2025.

772K


Voluntary medical male circumcisions were conducted for HIV prevention in 2024.

Tuberculosis Progress toward global targets




TB deaths: progress toward the WHO target*

In countries where the Global Fund invests



TB incidence rate: progress toward the WHO target

In countries where the Global Fund invests




*TB deaths include HIV-positive. "Continuation of recent trend" projection is based on reverting to pre-COVID-19 (2014-2019) trends. "Global target pathway to 2030" is based on targets from the WHO End TB Strategy. Countries that have recently received Global Fund TB funding and have reported programmatic results over the past two cycles.

Tuberculosis Trends





Trends in TB deaths (excluding HIV-positive)*

In countries where the Global Fund invests



Trends in new TB cases (all forms)

In countries where the Global Fund invests



*While major control efforts for malaria and HIV began with the launch of the Millennium Development Goals in 2000, TB control efforts began much earlier. The counterfactual and actual results therefore diverged from each other much earlier, making this graph look considerably different than its HIV and malaria counterparts.

The TB burden estimates are from the WHO Global Tuberculosis Report 2024. The estimation of “no TB control” trends for TB deaths from WHO and for new TB cases is based on the assumption of a constant trend in new TB cases since 2000.


Tuberculosis Key results for 2024 in countries where we invest




7.4 million

People treated for TB*


TB treatment coverage



TB treatment success rate (all forms)



HIV+ TB patients on ARVs



*Programmatic results achieved during 2024 by countries and regions where the Global Fund invests. Progress graphs are based on latest published data from WHO (2024 release for TB and malaria) and UNAIDS (2025 release). Malaria mosquito net coverage calculated based on 38 African countries for which data is available from WHO/Malaria Atlas Project estimates.



Key Results

In countries where the Global Fund invests:

7.4M

People were **treated for TB** in 2024.

317K

HIV-positive TB patients were on antiretroviral therapy during TB treatment in 2024; coverage of antiretroviral drugs in people with HIV and TB increased from 45% in 2010 to 91% in 2023. Global target: 100% among detected cases.

3.4M

People in contact with TB patients received **preventive therapy** in 2024.

120K

People were **on treatment for drug-resistant TB** in 2024; treatment coverage reached 44% in 2023 and the multidrug-resistant TB treatment success rate increased from 51% in 2010 to 73% in 2021. Global targets: 90% multidrug-resistant TB treatment coverage and success by 2025.

2.2M

People living with HIV on **antiretroviral therapy initiated TB preventive therapy** in 2024.

75%

TB treatment coverage increased from 45% in 2010 to 75% in 2023, and the TB treatment success rate reached 88% in 2022. Global targets for coverage and treatment success rates: 90% by 2025.


Malaria Progress toward global targets



Malaria mortality rate: progress toward the WHO target

In countries where the Global Fund invests


— Historical trend — Continuation of recent trend — Global target pathway to 2030



Malaria incidence rate: progress toward the WHO target

In countries where the Global Fund invests

— Historical trend — Continuation of recent trend — Global target pathway to 2030




“Continuation of recent trend” projection is based on reverting to pre-COVID-19 (2014-2019) trends. “Global target pathway to 2030” is based on targets from the WHO Global Technical Strategy for Malaria. Countries that have recently received Global Fund malaria funding and have reported programmatic results over the past two cycles.

Malaria Trends




Trends in malaria deaths

In countries where the Global Fund invests



Trends in malaria cases

In countries where the Global Fund invests



Malaria burden estimates and estimation of "no malaria control" from WHO World Malaria Report 2024.


Malaria Key results in 2024 in countries where we invest




162 million

Insecticide-treated mosquito nets distributed*


Mosquito nets population coverage



Mosquito nets population use



Suspected malaria cases tested



*Programmatic results achieved during 2024 by countries and regions where the Global Fund invests. Progress graphs are based on latest published data from WHO (2024 release for TB and malaria) and UNAIDS (2025 release). Malaria mosquito net coverage calculated based on 38 African countries for which data is available from WHO/Malaria Atlas Project estimates.



Key Results

In countries where the Global Fund invests:

162M

Insecticide-treated mosquito nets were distributed to protect families from malaria in 2024.

173M

Cases of malaria were treated in 2024.

17.8M

Pregnant women received preventive therapy in 2024.

61%

Coverage of the population with access to an insecticide-treated net increased from 29% in 2010 to 61% in 2023, and coverage of the population using a net increased from 26% in 2010 to 53% in 2023. Global target: Universal access to vector control for populations at risk.

360M

Suspected cases of malaria were tested in 2024.

50.9M

Children received seasonal malaria chemoprevention in 2024.

27.2M

Structures were protected by indoor residual spraying (IRS) in 2024.*

*The Global Fund has transitioned from reporting “structures sprayed with IRS” to “people protected by IRS,” aligning with the WHO World Malaria Report IRS indicator. This shift will help us better assess what proportion of the population at risk is protected by malaria prevention tools, enabling more strategic and equitable resource allocation. Further information is available in the Results Report web annex.

Health and Community Systems



Accelerating progress through targeted systems investments

- In 2024, the Global Fund invested **US\$2.7 billion in health and community systems.**
- Between 2024-2026, our partnership is investing **approximately US\$6.1 billion*** in these systems – a **49% increase over the previous grant cycle** and the largest health systems investment in our history. An estimated US\$2.1 billion of this total comes from the reprioritization of funds from our COVID-19 Response Mechanism (C19RM).
- **These investments are being delivered at an unprecedented scale** and are significantly contributing to HIV, TB and malaria outcomes, while advancing Sustainable Development Goal 3 and supporting progress toward universal health coverage.

The Global Fund partnership is the largest multilateral grants provider for health and community systems.

*This figure is based on the recently endorsed Global Fund Strategy Committee methodology that integrates direct investments in resilient and sustainable systems for health (RSSH) and contributions to RSSH through investments in the fight against HIV, TB and malaria (contributory RSSH). The amount is derived from approved and signed grant budgets and RSSH-related catalytic investments and includes C19RM. This methodology excludes Global Fund Secretariat operating expenses.

Health and Community Systems


In 2024, our health and community systems investments focused on:

High-impact thematic areas:

- The health workforce
- Community systems
- Surveillance and data systems
- Laboratories
- Waste management
- Supply chains
- Medical oxygen


High-priority countries:

- Our Implementation Acceleration initiative, launched at the end of 2023 intensified support in 17 highest-priority countries while monitoring efforts continued in another 25 priority countries.



The Global Fund is the largest funder of medical oxygen in low- and middle-income countries.

The Global Fund/Brian Otieno



The Global Fund/Jiro Ose

Agility and Resilience

Strategic review,
operational efficiency and
sustainable transitions

We are supporting reprogramming and reprioritization of grants across our activities.

We are working to ensure that this process is **country-driven and involves meaningful engagement with key stakeholders.**

Sustained investment is crucial to avoid a dangerous resurgence of HIV, TB and malaria.

Since 2002, the Global Fund has disbursed approximately US\$24 billion – in both long-term investments and emergency funding – to challenging operating environments (COEs), including some countries facing the worst humanitarian crises.

Investing for Impact

An investment in the Global Fund is an investment in one of the world's most effective mechanisms against infectious diseases. Every dollar we receive drives measurable health outcomes, fuels economic returns and delivers exceptional value for money.


Since 2002, we have disbursed more than **US\$69.9 billion** to respond to HIV, TB and malaria and to strengthen systems for health across **more than 100 countries**.

In 2024, the Global Fund disbursed US\$4.8 billion.

In a context of constrained resources, smart investment like this is not optional – it's essential. The Global Fund works directly with countries as we strive to ensure every dollar we invest drives the greatest possible impact.


Investing for Impact

International grants provided by the Global Fund in 2024




 **26%**

of all international financing for **HIV**



 **73%**

of all international financing for **TB**



 **59%**

of all international financing for **malaria**

This data is provided by UNAIDS (for HIV) and the World Health Organization (for TB and malaria).

Thank you

Results Report 2025

Read more about the
Global Fund's Impact



70
million
lives saved
through the Global Fund
partnership.



The Global Fund to Fight
AIDS, Tuberculosis and Malaria

+41 58 791 1700
theglobalfund.org